The FDA drug approvals database lists a supplement action dated 21 October 2026 on NDA 021132, the application for linezolid held by Pfizer. The record available to us does not describe what the supplement changes.
Supplements to an established application commonly cover labelling, manufacturing or presentation changes. Without the content, this should be read as an administrative entry rather than a new indication or a safety finding. Prescribers who need the detail should check the current FDA label.
- Treat this as an administrative entry until the label change is published.
- Check the current linezolid label for any revised warnings before relying on older summaries.
- Linezolid availability and labelling in India are set by CDSCO, not the FDA.
Why it matters
Supplement actions on older antibiotics sometimes carry label revisions that are easy to miss.
Don't overread it
A supplement action is not a new indication, and the record does not say what changed.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for infectious diseases, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free